Biocon zooms as its arm, Viatris launch third Oncology Biosimilar ‘Abevmy’ in Canada
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Biocon is currently trading at Rs. 340.05, up by 17.10 points or 5.29% from its previous closing of Rs. 322.95 on the BSE.
The scrip opened at Rs. 325.55 and has touched a high and low of Rs. 340.65 and Rs. 325.55 respectively. So far 100617 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 420.25 on 11-Jun-2021 and a 52 week low of Rs. 314.90 on 25-Oct-2021.
Last one week high and low of the scrip stood at Rs. 347.05 and Rs. 317.10 respectively. The current market cap of the company is Rs. 40670.33 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.98% and 15.39% respectively.
Biocon’s subsidiary -- Biocon Biologics and Viatris Inc. have launched Abevmy (bBevadzumab) in Canada. Abevmy is a biosimilar to Roche's Avastine (Bevacizumab) and has been approved by Health Canada across four oncology indications.
Abevmy follows the launch of Viatris’ two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019-the first Trastuzumab approved in the country - and Fulphila (bPegfilgrastim), which was launched in 2020. In addition to the therapeutic area of oncology, Viatris Canada launched Hulio (bAdalimumab) in February 2021 for chronic inflammatory conditions. The Viatris Advocate program is also now available for Abevmy. The program offers support and resources for patients, their caregivers and their healthcare providers.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
